62 related articles for article (PubMed ID: 27067847)
1. [Individual Dose Adjustment of 5-Fluorouracil Based on Pharmacokinetic Monitoring May Improve the Outcome of FOLFOX for Metastatic Colorectal Cancer].
Muneoka K; Shirai Y; Sasaki M; Sakata J; Kanda J; Wakabayashi H; Wakai T
Gan To Kagaku Ryoho; 2016 Mar; 43(3):323-6. PubMed ID: 27067847
[TBL] [Abstract][Full Text] [Related]
2. Individual fluorouracil dose adjustment in FOLFOX based on pharmacokinetic follow-up compared with conventional body-area-surface dosing: a phase II, proof-of-concept study.
Capitain O; Asevoaia A; Boisdron-Celle M; Poirier AL; Morel A; Gamelin E
Clin Colorectal Cancer; 2012 Dec; 11(4):263-7. PubMed ID: 22683364
[TBL] [Abstract][Full Text] [Related]
3. Personalized dosing via pharmacokinetic monitoring of 5-fluorouracil might reduce toxicity in early- or late-stage colorectal cancer patients treated with infusional 5-fluorouracil-based chemotherapy regimens.
Kline CL; Schiccitano A; Zhu J; Beachler C; Sheikh H; Harvey HA; Mackley HB; McKenna K; Staveley-O'Carroll K; Poritz L; Messaris E; Stewart D; Sivik J; El-Deiry WS
Clin Colorectal Cancer; 2014 Jun; 13(2):119-26. PubMed ID: 24461492
[TBL] [Abstract][Full Text] [Related]
4. Australian experience of a modified schedule of FOLFOX with high activity and tolerability and improved convenience in untreated metastatic colorectal cancer patients.
Goldstein D; Mitchell P; Michael M; Beale P; Friedlander M; Zalcberg J; White S; Clarke S
Br J Cancer; 2005 Mar; 92(5):832-7. PubMed ID: 15756253
[TBL] [Abstract][Full Text] [Related]
5. [Role of pharmacokinetic monitoring of serum fluorouracil concentration in patients with local advanced and metastatic colorectal cancer and further improving efficacy of fluorouracil-based chemotherapy].
Cai X; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
Zhonghua Zhong Liu Za Zhi; 2012 Jan; 34(1):39-43. PubMed ID: 22490854
[TBL] [Abstract][Full Text] [Related]
6. Oxaliplatin in patients with metastatic colorectal cancer: efficacy and pharmacokinetics parameters.
Burz C; Berindan-Neagoe I; Balacescu O; Todor N; Pelau D; Floares C; Kacso G; Tanaselia C; Ursu M; Vlase L; Leucuta SE; Cristea V; Irimie A
J BUON; 2010; 15(2):263-9. PubMed ID: 20658719
[TBL] [Abstract][Full Text] [Related]
7. Capecitabine plus oxaliplatin (XELOX) versus 5-fluorouracil/leucovorin plus oxaliplatin (FOLFOX-6) as first-line treatment for metastatic colorectal cancer.
Ducreux M; Bennouna J; Hebbar M; Ychou M; Lledo G; Conroy T; Adenis A; Faroux R; Rebischung C; Bergougnoux L; Kockler L; Douillard JY;
Int J Cancer; 2011 Feb; 128(3):682-90. PubMed ID: 20473862
[TBL] [Abstract][Full Text] [Related]
8. Oxaliplatin plus 5-fluorouracil/leucovorin (FOLFOX-4) as salvage chemotherapy in patients with pretreated colorectal cancer.
Shitara K; Munakata M; Muto O; Kasai M; Okada R; Mitobe S; Sakata Y
Gan To Kagaku Ryoho; 2007 Jul; 34(7):1079-84. PubMed ID: 17637544
[TBL] [Abstract][Full Text] [Related]
9. Modification of leucovorin dose within a simplified FOLFOX regimen improves tolerability without compromising efficacy.
Clarke S; Goldstein D; Mitchell P; Michael M; Beale P; Friedlander M; Zalcberg J; White S
Clin Colorectal Cancer; 2007 Jul; 6(8):578-82. PubMed ID: 17681104
[TBL] [Abstract][Full Text] [Related]
10. Individual fluorouracil dose adjustment based on pharmacokinetic follow-up compared with conventional dosage: results of a multicenter randomized trial of patients with metastatic colorectal cancer.
Gamelin E; Delva R; Jacob J; Merrouche Y; Raoul JL; Pezet D; Dorval E; Piot G; Morel A; Boisdron-Celle M
J Clin Oncol; 2008 May; 26(13):2099-105. PubMed ID: 18445839
[TBL] [Abstract][Full Text] [Related]
11. [Clinical significance of bolus 5-fluorouracil for recurrent or metastatic colorectal cancer treated with FOLFOX+ BevacizumabTherapy].
Yoshida Y; Hasegawa J; Nishimura J; Hirota M; Kim Y; Nezu R
Gan To Kagaku Ryoho; 2011 Aug; 38(8):1293-6. PubMed ID: 21829066
[TBL] [Abstract][Full Text] [Related]
12. [FOLFOX as adjuvant chemotherapy after curative resection of distant metastatic lesions in patients with colorectal cancer].
Nozawa H; Kitayama J; Sunami E; Saito S; Kanazawa T; Kazama S; Yazawa K; Kawai K; Mori K; Nagawa H
Gan To Kagaku Ryoho; 2011 Oct; 38(10):1627-32. PubMed ID: 21996957
[TBL] [Abstract][Full Text] [Related]
13. [Adjuvant Systemic Chemotherapy with S-1/Oxaliplatin or mFOLFOX6 after Curative Resection of Distant Metastases in Patients with Colorectal Cancer].
Miyata R; Kameyama N; Tomita M; Mitsuhashi H; Baba S; Amada E
Gan To Kagaku Ryoho; 2016 Mar; 43(3):327-30. PubMed ID: 27067848
[TBL] [Abstract][Full Text] [Related]
14. [Efficacy and safety of bevacizumab (BEV) plus chemotherapeutic agents in the treatment of metastatic colorectal cancer, mCRC].
Guo X; Liu TS; Yu YY; Zhou YH; Chen Y; Zhuang RY; Cui YH
Zhonghua Zhong Liu Za Zhi; 2013 Aug; 35(8):604-7. PubMed ID: 24314219
[TBL] [Abstract][Full Text] [Related]
15. Cediranib plus FOLFOX/CAPOX versus placebo plus FOLFOX/CAPOX in patients with previously untreated metastatic colorectal cancer: a randomized, double-blind, phase III study (HORIZON II).
Hoff PM; Hochhaus A; Pestalozzi BC; Tebbutt NC; Li J; Kim TW; Koynov KD; Kurteva G; Pintér T; Cheng Y; van Eyll B; Pike L; Fielding A; Robertson JD; Saunders MP
J Clin Oncol; 2012 Oct; 30(29):3596-603. PubMed ID: 22965965
[TBL] [Abstract][Full Text] [Related]
16. Results of adjuvant FOLFOX regimens in stage III colorectal cancer patients: retrospective analysis of 667 patients.
Uncu D; Aksoy S; Çetin B; Yetişyiğit T; Özdemir N; Berk V; Dane F; Inal A; Harputluoğlu H; Budakoğlu B; Koca D; Sevinç A; Cihan S; Durnalı AG; Özkan M; Öztürk MA; Işıkdoğan A; Büyükberber S; Benekli M; Köş T; Alkış N; Karaca H; Turhal NS; Zengin N;
Oncology; 2013; 84(4):240-5. PubMed ID: 23392240
[TBL] [Abstract][Full Text] [Related]
17. Phase I/II study of oxaliplatin with weekly bolus fluorouracil and high-dose leucovorin (ROX) as first-line therapy for patients with colorectal cancer.
Yamada Y; Ohtsu A; Boku N; Miyata Y; Shimada Y; Doi T; Muro K; Muto M; Hamaguchi T; Mera K; Yano T; Tanigawara Y; Shirao K
Jpn J Clin Oncol; 2006 Apr; 36(4):218-23. PubMed ID: 16684860
[TBL] [Abstract][Full Text] [Related]
18. The efficacy and toxicity of FOLFOX regimen (a combination of leucovorin and fluorouracil with oxaliplatin) as first-line treatment of metastatic colorectal cancer.
Matsushita H; Tsuboi K; Honda I; Kato N; Okochi O; Kobayashi D; Hattori M
Gan To Kagaku Ryoho; 2009 May; 36(5):797-801. PubMed ID: 19461180
[TBL] [Abstract][Full Text] [Related]
19. Cost effectiveness analysis of pharmacokinetically-guided 5-fluorouracil in FOLFOX chemotherapy for metastatic colorectal cancer.
Goldstein DA; Chen Q; Ayer T; Howard DH; Lipscomb J; Harvey RD; El-Rayes BF; Flowers CR
Clin Colorectal Cancer; 2014 Dec; 13(4):219-25. PubMed ID: 25306485
[TBL] [Abstract][Full Text] [Related]
20. The role of IVS14+1 G > A genotype detection in the dihydropyrimidine dehydrogenase gene and pharmacokinetic monitoring of 5-fluorouracil in the individualized adjustment of 5-fluorouracil for patients with local advanced and metastatic colorectal cancer: a preliminary report.
Cai X; Fang JM; Xue P; Song WF; Hu J; Gu HL; Yang HY; Wang LW
Eur Rev Med Pharmacol Sci; 2014; 18(8):1247-58. PubMed ID: 24817302
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
